The new rotavirus vaccines RV5 and RV1 have been associated with small increase in intussusception risk in active vaccine surveillance studies. It is unclear what the impact might be on the overall trends of intussusception hospitalizations at a large population basis.
We conducted an ecological study of hospital discharges of infants with intussusception discharge diagnosis using the California Office of Statewide Health Planning and Development database (1985–2010). We measured incidence rates (IR) of intussusception hospitalizations per 100,000 births within 3 periods (1985–1997; 2000–2005; 2006–2010) related to past, pre-introduction and post-introduction of the new rotavirus vaccines. We estimated slopes of yearly IRs within each period, changes in slopes between periods and IR ratios (IRR) of the mean IRs between periods. We did subgroup analyses for 5 age-subgroups. We also analyzed intussusception hospitalizations of infants who also had a surgical repair and/or radiologic reduction procedure code (restricted cohort).
We identified 6241 intussusception hospitalizations; 4696 also had pertinent procedure codes. There was an upward trend in yearly IRs during 2006–2010 (+2 excess cases per 100,000 births per year; P = 0.023); the change in slopes between 2006–2010 and 2000–2005 was +3.2 excess cases per 100,000 births per year (P = 0.052), and the IR in 2006–2010 was 10% higher than in 2000–2005 (IRR: 1.10; 95% confidence intervals: 1.01–1.19). The IRR in 2006–2010 versus 2000–2005 for the 6–14 weeks age-subgroup was 1.90 (95% confidence intervals: 1.33–2.74). In the restricted cohort, trends were similar, though not nominally significant.
We documented at a population-level a small increased risk in intussusception hospitalizations post-introduction of the new rotavirus vaccines.
Supplemental Digital Content is available in the text.
From the *Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Stanford, California; † Palo Alto Medical Foundation Research Institute, Palo Alto, California; and ‡Department of Health Research and Policy, Stanford University School of Medicine, Stanford, California
Accepted for publication December 17, 2014.
The authors have no conflicts of interest or funding to disclose.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (www.pidj.com).
Address for correspondence: Despina Contopoulos-Ioannidis MD, Division of Infectious Diseases, Department of Pediatrics, Stanford University School of Medicine, Room G312, 300 Pasteur Drive, Stanford CA 94305. E-mail: email@example.com.